Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Common Variable Immunodeficiency

Common Variable Immunodeficiency

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Common Variable Immunodeficiency

7 trials tracked for Common Variable Immunodeficiency: 6 in phase 3 or 4 and 1 with published results. The most-cited published study has 4 citations.

7Trials tracked
6Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 3 4 Phase 2 1
  1. Phase 3 Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases Completed · 4 cited
  2. Phase 4 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Completed
  3. Phase 4 Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency Completed
  4. Phase 3 Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases Completed
  5. Phase 3 Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) Completed
  6. Phase 3 Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy Completed
Show 1 more trials
  1. Phase 2 Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Common Variable Immunodeficiency: what the trials found

Clinical evaluations of various immunoglobulin treatments for Common Variable Immunodeficiency have established specific safety and efficacy profiles. Gammaplex was associated with a statistically significant incidence of adverse events (p=0.01) in a Phase 4 study 1. Additionally, trials were conducted evaluating the use of Gammaplex (5%) 3 and Subgam 4.

Data regarding patient outcomes for intravenous and subcutaneous immunoglobulin therapies indicate specific metrics for morbidity. Patients receiving Human Immunoglobulins Intravenous reported an average of 8.5 days out of work/school due to illness and 0.0 days of hospitalization 5. For patients receiving Human Normal Immunoglobulin for Subcutaneous Administration (IGSC), the annual rate was 8.00 days out of work/school and 3.48 days of hospitalization due to infections 6.

Quality of life assessments were conducted using standardized tools in a Phase 4 study involving Vivaglobin. Results for the SF-36 (Age ≥ 14 Years) ranged from 54.40 to 80.00, while results for the CHQ-PF50 (Age ≤ 13 Years) ranged from 74.06 to 100.00 2.

Recent results — preliminary, needs further review

  • A Phase 2 trial of Thiotepa (single daily dose) reported 0% graft rejection/failure and 100% survival at 24 months post-transplant, though these findings are not yet corroborated 7.

For the clinician treating this condition

  • Immunoglobulin therapies show measurable impacts on patient activity; intravenous administration was associated with 8.5 days out of work/school and 0.0 hospitalizations 5.
  • Subcutaneous administration (IGSC) resulted in an annual rate of 8.00 days out of work/school and 3.48 days of hospitalization due to infections 6.
  • Gammaplex was associated with a statistically significant rate of adverse events (p=0.01) 1.

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Subclinical humoral immune dysfunctions may drive gut-liver axis breakdown in pediatric MASLD
Diabetes & Endocrinology Sys. Review
Subclinical humoral immune dysfunctions may drive gut-liver axis breakdown in pediatric MASLD Immune system issues may drive liver disease in children
This mini-review explores the role of subclinical humoral immune dysfunctions, such as partial secretory IgA or IgG subclass deficiencies, i…
New research suggests that hidden immune system weaknesses could be a major driver of liver damage in children with fatty liver disease.
Frontiers Sep 18, 2026
Web-based tool improves phenotype capture for Common Variable Immunodeficiency in UK cohort
Allergy & Immunology Cohort
Web-based tool improves phenotype capture for Common Variable Immunodeficiency in UK cohort New Tool Maps Rare Immune Disease Patterns To Guide Treatment
This cohort study of 526 adults with Common Variable Immunodeficiency implemented a web-based Phenotype Capture Tool with clinician training…
A new tool now maps rare immune disease traits with high accuracy, helping doctors match patients to better treatments.
medRxiv Apr 29, 2026
Genomic analysis shows clonal Campylobacter persistence and gentamicin resistance in two CVID patients
Infectious Disease Cohort
Genomic analysis shows clonal Campylobacter persistence and gentamicin resistance in two CVID patients Why Your Chicken Could Be Making You Sick
This observational case series analyzed recurrent Campylobacter bacteremia in two patients with common variable immunodeficiency over 6 to 1…
New DNA testing shows people with weak immune systems get sick from the exact same chicken bacteria strain over many years, likely because t…
Frontiers Apr 10, 2026